CD274 and neoplasm: Several candidate biomarkers may help predict the efficacy of ICI immunotherapy and identify potential responders, including PD-L1 expression (8), tumor mutational burden (TMB) (9), immune regulatory mRNA expression signatures (10), and microsatellite instability-high (MSI-H)/mismatch-repair deficiency (dMMR) (11, 12).